Skye Bioscience (SKYE) Total Current Liabilities (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Total Current Liabilities of $10.4 million for Q1 2026, up 95.6% year-over-year from $5.3 million in Q1 2025, and up 26.8% quarter-over-quarter from $8.2 million in Q4 2025.
Skye Bioscience (SKYE) Total Current Liabilities (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Total Current Liabilities for 15 consecutive years, with $10.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 95.6% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (up 95.6% YoY), while the FY2025 annual figure was $8.2 million, up 89.11% from the prior year.
- Total Current Liabilities improved to $10.4 million in Q1 2026 per SKYE's latest filing, from $8.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $15.8 million in Q1 2024 and bottomed at $4.2 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $9.1 million across 5 years, with a median of $8.4 million in 2025.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 1211.43% — and 2024, when it tumbled 68.79%.
- Skye Bioscience's Total Current Liabilities stood at $12.1 million in 2022, then rose by 14.7% to $13.9 million in 2023, then sank by 68.79% to $4.3 million in 2024, then jumped by 89.11% to $8.2 million in 2025, then rose by 26.8% to $10.4 million in 2026.
- Business Quant data shows SKYE's Total Current Liabilities at $10.4 million in Q1 2026, $8.2 million in Q4 2025, and $8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 11.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.40 Mn |
| Dec 31, 2025 | 8.21 Mn |
| Sep 30, 2025 | 8.37 Mn |
| Jun 30, 2025 | 8.31 Mn |
| Mar 31, 2025 | 5.32 Mn |
| Dec 31, 2024 | 4.34 Mn |
| Sep 30, 2024 | 5.62 Mn |
| Jun 30, 2024 | 14.32 Mn |
| Mar 31, 2024 | 15.80 Mn |
| Dec 31, 2023 | 13.90 Mn |
| Sep 30, 2023 | 13.72 Mn |
| Jun 30, 2023 | 9.82 Mn |
| Mar 31, 2023 | 9.37 Mn |
| Dec 31, 2022 | 12.12 Mn |
| Sep 30, 2022 | 6.15 Mn |
| Jun 30, 2022 | 5.24 Mn |
| Mar 31, 2022 | 4.18 Mn |
| Dec 31, 2021 | 3.91 Mn |
| Sep 30, 2021 | 497,390.00 |
| Jun 30, 2021 | 1.55 Mn |